Peter A. Thompson - 14 Jun 2022 Form 4 Insider Report for Janux Therapeutics, Inc. (JANX)

Reporting relationship: Director
Issuer ticker: JANX
Reported as of: 14 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2022, 16:35:01 UTC
Prior SEC filing: 13 Jun 2022
Next SEC filing: 17 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Maria Dobek, Attorney-in-Fact

Key filing fact

Peter A. Thompson filed Form 4 for Janux Therapeutics, Inc. (JANX) on 16 Jun 2022.

Key facts

This page summarizes Peter A. Thompson's Form 4 filing for Janux Therapeutics, Inc. (JANX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2022, 16:35.

Change

Previous filing in this sequence was filed on 13 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

JANX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +12,500
Change %
Price: $0.000000
Shares after: 12,500
Date: 14 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,500
Exercise price: $10.73
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2022, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VIII, LP.